Background and Targets

Since antibiotics and other anti-infective drugs first became widely used, they have saved many lives and controlled serious complications of many diseases and infections More than 50 years of widespread use in hospital and community has created major evolutionary pressure in bacteria to evolve toward resistance; antimicrobial resistance provides a survival benefit to microbes and makes it harder to eliminate infections from the body. Diseases such as tuberculosis, malaria, nosocomial infections are now more difficult to treat than a few decades ago.

The resulting problem leads to increased morbidity, mortality and health costs. Referring to optional drugs (likewise penicillins, cefalosphorins, quinolons, even Vancomycin, the last one in rare/border-line cases) in some case we have exhausted a series of anti-infectious instruments actually available.

As regards the range of “new molecules for anti-infectious drugs” products, TYDOCKPHARMA founds its own researches on folate pathway including Thimidylate synthase an enzymatic protein involved in cellular replication.

More recently, a new thymidylate synthase protein (ThyX), has been isolated and its presence has been detected in numerous pathogenic species (not in human cells). Since this one seems not to be present in human, it might be possible for us to provide specific and safe drugs candidate with higher safety profile.